Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay

Click to increase image sizeClick to decrease image size

Acknowledgements

The THAOS registry and this analysis were sponsored by Pfizer. We thank all THAOS patients and investigators for their important contributions to this study. We also thank Pritam Gupta for statistical support on the manuscript. Medical writing support was provided by Emily Balevich, PhD, of Engage Scientific Solutions and was funded by Pfizer.

Disclosure statement

Teresa Coelho reports serving as a medical advisor for Pfizer and receiving funding for scientific meeting expenses (travel, accommodation and registration) from Pfizer. Angela Dispenzieri reports research grants from Celgene, Millennium, Pfizer, Janssen and Alnylam; funding from Pfizer for meeting expenses (travel); and attending advisory boards for Akcea and Intellia. Martha Grogan reports grants and advisory board and consultancy fees paid to her institution from Alnylam, Eidos, Prothena and Pfizer. Isabel Conceição reports consulting fees and funding for scientific meeting expenses (travel, accommodation and registration) from Pfizer. Márcia Waddington-Cruz reports research funding, consulting fees and travel support for advisory boards and meetings from FoldRx Pharmaceuticals and Pfizer. Arnt V. Kristen reports reimbursement for study visits from Pfizer during the conduct of the study. Jonas Wixner reports consulting fees and travel support for lectures and advisory boards from Pfizer and Alnylam; and consulting fees from Akcea and Intellia. Igor Diemberger received speaker fees from Biotronik, Boston Scientific, Daiichi Sankyo, Medtronic, Pfizer and Philips outside the submitted work. Juan Gonzalez-Moreno reports speaker fees from Pfizer, Alnylam and Akcea. Mathew S. Maurer reports grants from Pfizer during the conduct of the study; grants and personal fees from Pfizer, Eidos, Prothena and Ionis; grants from Alnylam; and personal fees from GSK and Akcea outside the submitted work. Violaine Planté-Bordeneuve reports serving as a medical advisor for Pfizer, Alnylam, Eidos and Ionis. Pablo Garcia-Pavia reports speaking fees from Pfizer, Eidos, Alnylam and Akcea; consulting fees from Pfizer, Eidos, Neurimmune, Alnylam, Prothena and Akcea; and research/educational support to his institution from Pfizer, Eidos and Alynylam. Ivailo Tournev reports speakers bureau/lecturer fees from Ewopharma, Genesis Pharma, Pfizer, Roche and Sanofi. Jose Gonzalez-Costello reports attending advisory boards for Pfizer and Alnylam. Eve Cariou has no conflicts to report. Alejandra González-Duarte reports financial support from Alnylam and Pfizer for her role as a principal investigator in studies sponsored by these entities, and as a consultant and speaker. Oliver Glass, Doug Chapman and Leslie Amass are full-time employees of Pfizer and hold stock and/or stock options in Pfizer. No potential conflict of interest was reported by the author(s).

Data availability statement

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.